Anti-NASH Drug Development Hitches a Lift on PPAR Agonism

Non-alcoholic fatty liver disease (NAFLD) affects one-third of the population worldwide, of which a substantial number of patients suffer from non-alcoholic steatohepatitis (NASH). NASH is a severe condition characterized by steatosis and concomitant liver inflammation and fibrosis, for which no dru...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cells
Main Authors: Boeckmans, Joost, Natale, Alessandra, Rombaut, Matthias, Buyl, Karolien, Rogiers, Vera, De Kock, Joery, Vanhaecke, Tamara, Rodrigues, Robim M.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016963/
https://ncbi.nlm.nih.gov/pubmed/31877771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9010037
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados